Author:
Liu Joyce F.,Xiong Niya,Wenham Robert M.,Wahner-Hendrickson Andrea,Armstrong Deborah K.,Chan Nancy,O'Malley David M.,Lee Jung-Min,Penson Richard T.,Cristea Mihaela C.,Abbruzzese James L.,Matsuo Koji,Olawaiye Alexander B.,Barry William T.,Cheng Su-Chun,Polak Madeline,Swisher Elizabeth M.,Shapiro Geoffrey I.,Kohn Elise C.,Ivy S. Percy,Matulonis Ursula A.
Reference35 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023
2. Ovarian cancer;Matulonis;Nat. Rev. Dis. Primers,2016
3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet,2017
4. Niraparib in patients with newly diagnosed advanced ovarian cancer;Gonzalez-Martin;N. Engl. J. Med.,2019
5. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N. Engl. J. Med.,2016